29 March 2022: Meta-Analysis
The Correlation of Mouse Double Minute 4 (MDM4) Polymorphisms (rs4245739, rs1563828, rs11801299, rs10900598, and rs1380576) with Cancer Susceptibility: A Meta-Analysis
Jian Chen 1ABCDEF , Xudong Li 2BCD , Ruihao Liu 1DEF , Yufen Xie 1DE , Zhigao Liu 1CE , Haiwei Xiong 1CE , Yingliang Li 1ACG*DOI: 10.12659/MSM.935671
Med Sci Monit 2022; 28:e935671
Supplementary Table 1 Assessment of the quality of the included studies by the Newcastle-Ottawa Scale (NOS).
| Author | Year | Cancer-type | Selection | Comparability | Exposure | Score | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Criteria 1 | Criteria 2 | Criteria 3 | Criteria 4 | Criteria 5 | Criteria 6 | Criteria 7 | Criteria 8 | ||||
| Garcia-Closas | 2013 | Breast cancer | * | * | – | * | * | * | – | – | 5 |
| JB Liu | 2013 | Breast cancer | * | * | * | * | ** | – | * | – | 7 |
| JB Liu | 2013 | Breast cancer | * | * | * | * | ** | – | * | – | 7 |
| LQ Zhou | 2013 | ESCC | * | * | * | * | ** | – | * | – | 7 |
| LQ Zhou | 2013 | ESCC | * | * | * | * | ** | – | * | – | 7 |
| CB Fan | 2014 | NHL | * | * | * | * | ** | – | * | – | 7 |
| JB Feng | 2014 | Gastric cancer | * | * | – | * | ** | – | * | – | 6 |
| Gansmo | 2015 | Breast cancer | * | * | * | * | ** | – | * | – | 7 |
| Gansmo | 2015 | Colon cancer | * | * | * | * | ** | – | * | – | 7 |
| Gansmo | 2015 | Lung cancer | * | * | * | * | ** | – | * | – | 7 |
| Gansmo | 2015 | Prostate cancer | * | * | * | * | ** | – | * | – | 7 |
| F Gao | 2015 | Lung cancer | * | * | * | * | ** | – | * | – | 7 |
| F Gao | 2015 | Lung cancer | * | * | * | * | ** | – | * | – | 7 |
| Pedram | 2016 | Breast cancer | * | * | – | * | ** | – | * | – | 6 |
| Gansmo | 2016 | Ovarian cancer | * | * | * | * | * | – | * | – | 6 |
| Gansmo | 2016 | Endometrial cancer | * | * | * | * | * | – | * | – | 6 |
| Khanlou | 2017 | Thyroid cancer | * | * | – | * | ** | – | * | – | 6 |
| Hashemi | 2018 | Breast cancer | * | * | – | * | ** | – | * | – | 6 |
| Pedram | 2020 | Breast cancer | * | * | * | * | ** | – | * | – | 7 |
| DM Zhao | 2020 | Colorectal cancer | * | * | – | * | ** | – | * | – | 6 |
| Kotarac | 2020 | Prostate cancer | * | * | – | * | ** | – | * | – | 6 |
| Tripon | 2020 | AML | * | * | – | * | * | * | * | – | 6 |
| CG Song | 2012 | Breast cancer | * | * | – | * | ** | – | * | – | 6 |
| YW Zhang | 2012 | NPC | * | * | * | * | ** | – | * | – | 7 |
| Thunell | 2014 | Hereditary melanoma | * | * | * | * | ** | – | * | – | 7 |
| HP Yu | 2011 | SCCHN | * | * | – | * | ** | * | * | – | 7 |
| HP Yu | 2012 | SCCHN | * | * | – | * | ** | * | * | – | 7 |
| GC Wu | 2015 | Gastric cancer | * | * | – | * | ** | – | * | – | 6 |
| MY Wang | 2017 | Gastric cancer | * | * | – | * | ** | – | * | – | 6 |
| Hashemi | 2018 | Breast cancer | * | * | – | * | ** | – | * | – | 6 |
| FH Yu | 2019 | Retino-blastoma | * | * | – | * | ** | – | * | – | 6 |
| HP Yu | 2011 | SCCHN | * | * | – | * | ** | * | * | – | 7 |
| HP Yu | 2012 | SCCHN | * | * | – | * | ** | * | * | – | 7 |
| MY Wang | 2017 | Gastric cancer | * | * | – | * | ** | – | * | – | 6 |
| Hashemi | 2018 | Breast cancer | * | * | – | * | ** | – | * | – | 6 |
| FH Yu | 2019 | Retino-blastoma | * | * | – | * | ** | – | * | – | 6 |
| HP Yu | 2011 | SCCHN | * | * | – | * | ** | * | * | – | 7 |
| HP Yu | 2012 | SCCHN | * | * | – | * | ** | * | * | – | 7 |
| MY Wang | 2017 | Gastric cancer | * | * | – | * | ** | – | * | – | 6 |
| Criteria 1 – adequate definition of case; Criteria 2 – representativeness of the case; Criteria 3 – selection of controls; Criteria 4 – definition of controls; Criteria 5 – control for important factor; Criteria 6 – assessment of exposure; Criteria 7 – same method of ascertainment for cases and controls; Criteria 8 – non-response rate. | |||||||||||